Skip to search formSkip to main contentSkip to account menu

Anti-HER3 Monoclonal Antibody LJM716

Known as: LJM716 
A human monoclonal antibody directed against the human epidermal growth factor receptor HER3 (ErbB3) with potential antineoplastic activity. Anti… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminologyantigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
[Preparation and identification of single-chain fragment variable against epidermal growth factor receptor 3].
Objective To express, purify and identify the single-chain fragment variable (scFv) against human epidermal growth factor… 
2017
2017
Abstract P6-12-09: Pan-HER, an antibody mixture with antitumor activity against drug-resistant HER2-overexpressing breast cancers with high ERBB ligand expression
Background: Amplification/overexpression of ERBB receptors and/or ligands has been associated with resistance to anti-HER2… 
2015
2015
Abstract OT3-1-05: Phase I, open-label study evaluating the safety and tolerability of LJM716, BYL719 and trastuzumab in patients with metastatic HER2+ breast cancer
Background: Breast cancers that overexpress the human epidermal growth factor receptor 2 (HER2+) are driven by HER2/HER3/PI3K… 
2015
2015
Abstract 5421: HER3 inhibition has little efficacy on hepatocellular carcinoma cell lines
Background: HER3 is a member of the ErbB family of receptor tyrosine kinases that are involved in the pathogenesis of many… 
2014
2014
A phase 1 study of LJM716 in patients with esophageal squamous cell carcinoma, head and neck cancer, or HER2-overexpressing metastatic breast or gastric cancer.
2517 Background: The HER3 receptor is important for maintenance of EGFR- and HER2-driven cancers and targeted therapy resistance… 
2014
2014
Abstract 2612: ljm716, an anti her3 antibody that inhibits her3 dimerization, displays anti-tumor activity in esophageal squamous cell cancer
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA Background: Esophageal cancer is the eighth most common… 
2014
2014
Abstract LB-237: Targeting HER3 and IGF1R in NRG1 high lung squamous cell carcinoma
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA HER3 is a member of the ErbB family of receptor tyrosine… 
2013
2013
Abstract 4261: Targeting HER3 and PI3K in head and neck squamous cancer cells.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Background: Head and neck squamous cell carcinoma… 
2013
2013
Therapeutics , Targets , and Chemical Biology Combination of Antibody That Inhibits Ligand-Independent HER 3 Dimerization and a p 110 a Inhibitor Potently Blocks PI 3 K Signaling and Growth of HER 2…
  • 2013
  • Corpus ID: 33925111
We examined the effects of LJM716, an HER3 (ERBB3) neutralizing antibody that inhibits ligand-induced and ligand-independent HER3… 
2013
2013
Abstract 5461: A HER3 antibody that blocks ligand-independent HER2-HER3 dimerization sensitizes to HER2 and PI3K inhibitors .
We hypothesized that complete inhibition of HER3 is required for the optimal action of HER2 or PI3K/Akt inhibitors against HER2… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)